key: cord-1034250-87bmdv7e
authors: Qu, Jiuxin; Cai, Zhao; Liu, Yumei; Duan, XiangKe; Han, Shuhong; Zhu, Yuao; Jiang, Zhaofang; Zhang, Yingdan; Zhuo, Chao; Liu, Yang; Liu, Yingxia; Liu, Lei; Yang, Liang
title: Persistent bacterial coinfection of a COVID-19 patient caused by a genetically adapted Pseudomonas aeruginosa chronic colonizer
date: 2020-08-06
journal: bioRxiv
DOI: 10.1101/2020.08.05.238998
sha: dd3cb2f700bff25c60af9affc457d5ce5754f74e
doc_id: 1034250
cord_uid: 87bmdv7e

This study characterized a genetically adapted Pseudomonas aeruginosa small colony variant isolated from a COVID-19 patient who suffered persistent bacterial coinfection and eventually recovered from critical illness. Specification and modification of the isolates discovered at genomic and transcriptomic levels with aligned phenotypic observations indicated that these isolates formed excessive biofilm with elevated quorum sensing systems.

The characteristics, pathogenicity, epidemiology and treatments of SARS-CoV-2 viral infection has been extensively studied since the onset of the 2019 novel coronavirus (COVID-19) pandemic. [1] [2] [3] COVID-19 infection leads to huge impact on the immunity of patients' respiratory tracks and causes multiple organ damages. [4, 5] Viral infection in the respiratory tract is often accompanied with co-infecting bacterial pathogens. Viral invasion to the respiratory system alters functions and composition of respiratory microbiota which often leads to the onset of secondary bacterial infection. Bacterial coinfection significantly increases the mortality rate of patients while Pseudomonas aeruginosa was identified as one of most common co-infecting bacteria during viral infection in respiratory system such as H1N1 pneumonia. [6] [7] [8] P. aeruginosa is well known to adapt to the respiratory environments by genetic modification to reduce virulence, increase antimicrobial resistance and enhance biofilm formation in immunocompromised individuals with chronic diseases such as cystic fibrosis. [9, 10] However, survival of P. aeruginosa in the SARS-CoV-2 infected respiratory tract and its impact on the patients still remain unclear. To investigate the adaptation of P. aeruginosa during coinfection with SARS-CoV-2 virus, we characterized two P. aeruginosa small-colony variants (SCVs) isolated from sputum samples of a COVID-19 patient who was eventually recovered from critical illness.

Two isolates of P. aeruginosa were collected from sputum samples of one COVID-19 patient with 10 days interval (Isolate 1 on 12 February 2020 and Isolate 2 on 22 February 2020) during routine clinical tests. Bacterial antimicrobial susceptibility of P.aeruginosa with different colony morphologies, including ceftazidime, piperacillin, cefoperazone/sulbactam, imipenem, aztreonam, and levofloxacin, were performed using the Kirby-Bauer discdiffusion method. The protocol of K-B method and interpretations of results were based on the Clinical and Laboratory Standards Institute [11] . Susceptibility was listed in Table S8 .

Genomes of both P. aeruginosa isolates were extracted and sequenced by Illumina HiSeq X platform and genome of Isolate 1(Iso1) was sequenced by PacBio Sequel II platform. RNA of two isolates and the P. aeruginosa reference PAO1 strain were collected in duplicate and sequenced by Illumina NovaSeq platform. Resequencing analysis was performed to identify Single Nucleotide Polymorphism (SNP) in isolates. PacBio sequence reads was assembled to full genome of Iso 1. Multilocus sequence typing (MLST) was performed to classify the isolates while antimicrobial resistance genes (ARGs) of the isolates were identified.

Phylogenetic tree and genomic islands were predicted to trace the origin and identify the specific genomic regions of the isolates. RNA-seq analysis and GO enrichment were performed to investigate the differential gene expression and functional enrichment of the isolates.

All strains and plasmids used are listed in Table S1 . Overnight cultures of the isolates and PAO1 were diluted and incubated for biofilm formation assay. Biofilm biomass was quantified using crystal violet (CV) staining. Swimming and swarming motility of these strains were tested. Quorum sensing (QS) activities of the isolates, PAO1 and PAO1ΔlasIΔrhlI mutant (QS negative control strain) was assessed using sterile supernatants of these strains and PAO1ΔlasIΔrhlI double mutant harboring either lasB-gfp or rhlA-gfp reporter. Levels of cyclic-di-GMP in the isolates and PAO1 were measured by monitoring GFP/OD level of transformants of these strains carrying cdrA-gfp reporter. All methods are fully described in supplementary documents.

The patient was admitted to our hospital with confirmed COVID-19 infection on 23 January 2020 and hospitalized for 45 days with course of disease of 47 days. The patient received combined antiviral, antimicrobial and anti-inflammatory treatments during hospitalization with immunity enhancing medication and traditional Chinese medicines. (Table S2 ) Counts of white blood cells (WBC), neutropihls (N), lymphocytes(L) and level of Interleukin-6 (IL-6) were recorded as immune response indicators. (Table S2 ) The patient turned into critical illness from day 4 to day 32. The first immune response peak was seen at day 7 of hospitalization.( Figure 1S ) After receiving treatments, immune response stablized for about 2 weeks and elevated again from day 21 to day 31 with a milder peak.( Figure 1S ) The onset of second immune response coincided with the isolation time of P. aeruginosa from sputum samples. P. aeruginosa persisted in the patient's respiratory system and could not be eliminated by antimicrobial treatments during the period of critical illness. This suggests that P. aeruginosa may play an important role in SARS-CoV-2 coinfection during critical illness and lead to secondary infection. It is a possible cause of the second peak of immune response observed. Thus, two P. aeruginosa isolates were collected on day 21 (Iso 1) and day 31 (Iso 2) for further analysis to understanding their genetic and phenotypic characteristics leading to such observation which may contribute to the prognosis of disease development and treatment scheme decision.

The morphology of the two isolates revealed that they are SCVs of P. aeruginosa with overproduction of exopolysaccharides. ( Figure 1E ) MLST analysis showed that both isolates are P. aeruginosa ST 1445, indicating they are the same strain with different evolving times.

The complete genome of Iso 1 were assembled and closed with a total length of 6,552,237 bp, average 66.21 % GC and 6239 genes predicted.

Phylogenetic tree was constructed by comparing Iso 1 genome to 23 other P. aeruginosa genomes selected from NCBI Genbank to trace its evolutionary origin. (Table S3) virulence and toxin transport, and transcriptional regulation, indicating that these specific GIs (Table S4) However, none of these genes was found locating in the predicted GIs.

To understand the genetic modification of the P. aeruginosa isolates evolved over time during SARS-CoV-2 coinfection, SNPs were identified by comparing the genomic sequences of Iso 2 to Iso 1. (Table S5) To further understand the adaptation mechanisms of these two P. aeruginosa isolates, we compared the transcriptomes of Iso 1, Iso 2 and the reference PAO1 strain. The clear separation of the isolates from PAO1 along PC1 (85%) on PCoA plot implied the significant differences in their transcriptomic profiles. (Figure 1C) The proximity between the clusters of two isolates along both PC1 (85%) and PC2 (9%) implied their transcriptional similarity.

were significantly downregulated (fold change ≦-4 and adjusted p-value < 0.05) in Iso 2 comparing to Iso 1 with mostly low mean counts. (Table S6 ) This showed that the isolates survived and proliferated stably during coinfection in COVID-19 patient's respiratory system.

Notably, two downregulated genes with high mean counts are involved in multidrug efflux system(mexC and mexD), indicating a lower capacity of antimicrobial resistance of Iso 2 comparing to Iso 1. Such change may contribute to the eventual clearance of P. aeruginosa by antimicrobial treatments. SNPs identified from Iso 2 had no significant effect on transcriptional expression. DGE of PAO1 was comparing with Iso2 only since there was only minimal difference between Iso 1 and Iso 2. 456 genes were significantly regulated in Iso 2 (absolute fold change ≧ 4 and adjusted p-value < 0.05, Table S7 ) while Gene Ontology(GO) enrichment were illustrated in Figure 1D . In Iso 2, cdrA(PA4625) was upregulated for 4.27 folds indicating an increased cyclic-di-GMP biosynthesis. [12] (Table 1, Figure 1I ) This increase in cyclic-di-GMP was most probably due to downregulation of arr gene which encodes for a phosphodiesterase catalyzing degradation of cyclic-di-GMP. [13] Moreover, PA2771 encoding a diguanylate cyclase for cyclic-di-GMP biosynthesis also downregulated significantly probably due to its self-inhibition induced upon binding with cyclic-di-GMP. [14] Cyclic-di-GMP promotes biofilm formation through various mechanism including increasing exopolysacchairdes formation and motility reduction. Iso 1 and Iso 2 formed excessive biofilm comparing to PAO1 as observed from phenotypic test.( Figure 1E&G ) GO enrichment showed that biosynthesis processes of alginate and lipopolysaccharides (LPS) were highly enriched. (Figure 1D ) Genes involved in biosynthesis of alginate (alg) and Pel (pel) was highly upregulated while those involved in LPS formation (wbp, wzx/y/z) were greatly downregulated. Previous studies had proved that alginate, Psl and Pel share the same precursors, mannose-1-phosphate, with LPS. [15] Thus, the increase in the exopolysaccharide of the isolates was due to the biosynthetic flux towards alginate and Pel leading to a reduction in LPS biosynthesis. As LPS is a virulence factor inducing host immune response, the immune response induced in the patient was probably not due to LPS expression. [16] Genes involved in flagellar formation were downregulated in Iso 2 leading to lower swimming and swarmming motility which further contributed to biofilm formation.(Table 1, Figure 1F ) An notable observation from the isolates was the upregulation of las and rhl QS systems.( Figure   1H ) Such observation was opposite from previous discovery which showed SCVs with more biofilm formation possessed suppressed QS systems to escape from host immune clearance. [17, 18] From DGE results, expression of lasB and rhlAB genes in Iso 2 were slightly upregulated for 1.62, 2.74 and 3.25 folds, respectively, which aligned with phenotypic observation. As QS is related to virulence, such observation possibly inferred that the isolates would have attacked the host tissue during critical illness and thus induced host immune responses instead of escaping from immune clearance by suppressing QS. We further found that erythromycin was effective in reducing such elevation of QS. (Figure S2 )

In this report, two SCVs of P. aeruginosa co-infecting with SARS-CoV-2 virus has been isolated from one critically illed COVID-19 patient and characterized at genomic, trancscriptomic and phenotypic levels. The isolates carry multiple specific GIs and several ARGs for survival, proliferation, drug-resistance and invasion in host's respiratory systems.

We demonstrated the alterations in biofilm-forming capability and QS expression in these Table 1 . Differential expression of genes involved in cyclic-di-GMP biosynthesis, biofilm formation and motility in PAO1 and Iso 2. 

Science and Technology Program of Shenzhen

and Guangdong Basic and Applied Basic Research Foundation [2020A1515010586] for Dr

Jiuxin Qu, and Grant from Bill & Melinda Gates Foundation to Dr

Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma

Comorbidities and multi-organ injuries in the treatment of COVID-19

Kidney involvement in COVID-19 and rationale for extracorporeal therapies

Respiratory Viral Infection-Induced Microbiome Alterations and Secondary Bacterial Pneumonia

Bacterial co-infection with H1N1 infection in patients admitted with community acquired pneumonia

Streptococcus pneumoniae coinfection is correlated with the severity of H1N1 pandemic influenza

Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients

Convergent evolution and adaptation of Pseudomonas aeruginosa within patients with cystic fibrosis

Performance Standards for Antimicrobial Susceptibility Testing. 29th ed. CLSI supplement M100

Pseudomonas aeruginosa uses a cyclic-di-GMP-regulated adhesin to reinforce the biofilm extracellular matrix

Aminoglycoside antibiotics induce bacterial biofilm formation

Dcsbis (PA2771) from Pseudomonas aeruginosa is a highly active diguanylate cyclase with unique activity regulation

Synthesis of multiple Pseudomonas aeruginosa biofilm matrix exopolysaccharides is post-transcriptionally regulated

Pseudomonas aeruginosa lipopolysaccharide: a major virulence factor, initiator of inflammation and target for effective immunity

Pseudomonas aeruginosa rugose smallcolony variants evade host clearance, are hyper-inflammatory, and persist in multiple host environments

Phenotypic and genome-wide analysis of an antibiotic-resistant small colony variant (SCV) of Pseudomonas aeruginosa

1A) Phylogenetic tree constructed using whole genomes of Iso 1 and 23 other P. aeruginosa laboratory, clinical and environmental strains selected from NCBI database

PAO1(lab reference strain); Circle 5: PA14(virulent clinical isolate)

Circle 7: DK2 (Strain isolated from Cystic Fibrosis patient)

Antimicrobial resistance genes; (1C) PCoA plot of PAO1, Iso 1 and Iso 2 by Bray Curtis dissimilarity based on normalized read counts of RNA-seq analysis; (1D) Gene Orthology Enrichment based on the significantly regulated genes (absolute fold change≧4, adjusted p-value<0.05) in Iso 2 comparing to that of PAO1. (1E) morphology of PAO1, Iso 1and Iso 2; (1F) Swimming and Swarming motility of PAO1, Iso 1 and Iso 2; (1G) Biofilm formation quantified by CV staining (p-value <0.05); (1H) las and rhl quorum sensing expression measured by lasB-gfp and rhlA-gfp reporters

The authors declare that they have no competing interests.

This work is approved by the Ethics Committee of Shenzhen Third People's Hospital, Second Hospital Affiliated to Southern University of science and Technology .